For example, a specific inhibitor of kallikrein (Ecallantide) and/or a bradykinin B2 receptor antagonist (Icatibant) could be used in patients with AE not caused by C1-INH deficiency. This evidence concerns the gene KLK4 and hyperinsulinemic hypoglycemia, familial, 4.